Aprea Therapeutics is progressing its Phase 1 ACESOT-1051 trial of APR-1051, a WEE1 inhibitor, showing promising tolerability in treating cancers with Cyclin E over-expression.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.